The market for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) was valued USD 968 Million in 2017 which is anticipated to reach USD 2,020.6 Million by 2030.

In a statement, Argenx said that the subcutaneously administered drug is the first “meaningful” new treatment option for the approximately 24,000 people living with CIDP in the US in more than ...

The newly approved prefilled syringe for self-injection of Vyvgart Hytrulo will provide more convenience and flexibility for ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) results in disability through immune-mediated nerve injury, which can lead to irreversible deficits after the inflammatory component of ...

In recent years, CIDP has received increasing attention due to its high misdiagnosis rate, along with the publication of new ...

27 Three clinical trials have attempted to compare first-line treatment options for CIDP; results are limited by inadequate power, imbalances in patient characteristics in treatment arms ...

The FDA has approved a subcutaneous self-injectable for adults with generalized myasthenia gravis who are anti-acetylcholine ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

Amsterdam, the Netherlands Thursday, April 10, 2025, 18:00 Hrs [IST] ...

"CIDP is a debilitating disorder which sees ... "It's great to see a new treatment option for patients affected by this neuromuscular disorder to give them a chance at better managing their ...

"Takeda remains committed to helping the millions of Canadians living with rare diseases like CIDP through the development of innovative new treatments to improve their quality of life." ...